Krebs Biochemicals and Industries working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5,482.99×	5,482.99×	519.93×	602.36×	266.59×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.42×	0.42×	8.23×	8.79×	4.91×
14,909.73×	14,909.73×	1,219.44×	948.91×	378.02×
−9,426.32×	−9,426.32×	−691.28×	−337.76×	−106.52×
−0.23×	−0.23×	−0.46×	−1.14×	−1.58×
0.14×	0.14×	0.25×	0.29×	0.29×
0.11×	0.11×	0.29×	−0.12×	1.07×
0.35×	0.35×	0.53×	−0.26×	1.68×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KREBSBIO₹57.93

Krebs Biochemicals and Industries Limited

· Pharma & Health

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹125 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Inventory Days (DIO)	266.59	602.36	519.93	5,482.99	5,482.99
Receivable Days (DSO)	4.91	8.79	8.23	0.42	0.42
Payable Days (DPO)	378.02	948.91	1,219.44	14,909.73	14,909.73
Cash Conversion Cycle (days)	-106.52	-337.76	-691.28	-9,426.32	-9,426.32
Working Capital Turnover	-1.58	-1.14	-0.46	-0.23	-0.23
Asset Turnover	0.29	0.29	0.25	0.14	0.14
Cash Conversion (CFO/Net Income)	1.07	-0.12	0.29	0.11	0.11
CFO/EBITDA	1.68	-0.26	0.53	0.35	0.35

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.